Novartis AG (NVS) annual results, year to 31 December 2017: revenue USD 42,381 million, from the 20-F
Novartis AG files a 20-F with the SEC once a year, in US dollars. In the year to 31 December 2017 it reported revenue from the sale of goods of USD 42,381 million, down 12.6% on the year before. Its profit attributable to shareholders was USD 7,703 million, up 14.8%, and diluted earnings per share USD 3.25.
The year to 31 December 2017, against the year before
| Year to | Dec 2016 | Dec 2017 † |
|---|---|---|
| Revenue from the sale of goods | 48,518 | 42,381 |
| Cost of sales | 17,520 | 13,633 |
| Gross profit | 31,916 | 29,771 |
| Research and development | 9,039 | 8,389 |
| Selling, general and administrative | 14,192 | 12,465 |
| Operating profit | 8,268 | 8,702 |
| Profit before tax | 7,817 | 9,102 |
| Income tax | 1,119 | 1,603 |
| Profit for the year | 6,698 | 7,703 |
| Profit attributable to shareholders | 6,712 | 7,703 |
| Filing | 20-F | 20-F |
USD million, from the 20-F on the SEC's EDGAR, linked in the last row, on the IFRS tags the company filed. A line the company does not file under the standard tag is left out rather than estimated.
USD per ordinary share, as filed.
Cash flow
| Year to | Dec 2016 | Dec 2017 † |
|---|---|---|
| Cash from operations | 11,475 | 12,621 |
| Purchase of property, plant and equipment | 1,862 | 1,325 |
| Free cash flow | 9,613 | 11,296 |
| Dividends paid | 6,475 | 6,495 |
| Filing | 20-F | 20-F |
USD million. Free cash flow is cash from operations less the purchase of property, plant and equipment, arithmetic on the two filed lines.
Balance sheet at year end
| Year to | Dec 2016 | Dec 2017 † |
|---|---|---|
| Total assets | n/a | 133,079 |
| Equity attributable to shareholders | 74,891 | 74,168 |
| Cash and cash equivalents | 7,007 | 8,860 |
| Borrowings, as filed | n/a | 23,583 |
| Inventories | n/a | 6,867 |
| Goodwill | n/a | 31,750 |
| Filing | 20-F | 20-F |
USD million, at each fiscal year end.
Ratios on the filed lines
| Year to | Dec 2016 | Dec 2017 † |
|---|---|---|
| Return on year-end equity | 9.0% | 10.4% |
| Effective tax rate | 14.3% | 17.6% |
| Filing | 20-F | 20-F |
Arithmetic on the filed lines of the same year.
Every annual report here
- Year to 31 December 2025
- Year to 31 December 2024
- Year to 31 December 2023
- Year to 31 December 2022
- Year to 31 December 2021
- Year to 31 December 2020
- Year to 31 December 2019
- Year to 31 December 2018
- Year to 31 December 2017, this page
- Year to 31 December 2016
Source
20-F for the year to 31 December 2017, filed 29 January 2020, accession 0001370368-20-000003: the filing on EDGAR. All of Novartis AG's filings: EDGAR company page. The figures are in US dollars as filed.
The same record on your computer
GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.